| Company Name: | Tanox, Incorporated | | Ticker Symbol: | TNOX | | | WWW Address: | www.tanox.com | | CEO: | Danong Chen | | No. of Employees: | 197 | | Common Issue Type: | CS | | Business Description: | The Company discovers and develops therapeutic monoclonal antibodies to address unmet medical needs in the areas of immune-mediated diseases, infectious disease, inflammation and cancer.
|
| | | Industry Information: | DRUGS - Drug Manufacturers - Other [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | |  | - | - | 0 | 19.73 | 19.50 | - |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 895.9 | 45.7 | 1.20 | -0.06 | 0.00 | 280.0 | 0.0 | 19.98 - 11.55 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 19.60 | $ | | PE Ratio - LTM | 280.0 | |
| Market Capitalisation | 895.9 | mil |
| Latest Shares Outstanding | 45.7 | mil |
| Earnings pS (EPS) | -0.06 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 284,959 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 32.4 | mil |
| Float as % of Shares Outstanding | 70.8 | % |
| Foreign Sales | 0 | mil |
| Domestic Sales | 0 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 25.40 | % |
| Research & Devlopment (R&D) as % of Revenue | 82.90 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | -1.1 | % |
| Pre-Tax Profit Margin | 5.1 | % |
| Assets Turnover | 0.3 | % |
| Return on Assets (ROA) | 1.3 | % |
| Return on Equity (ROE) | 1.4 | % |
| Return on Capital Invested (ROCI) | 1.4 | % |
| Current Ratio | 20.3 | |
| Leverage Ratio (Assets/Equity) | 1.0 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 3.88 | $ |
| Cash pS | 1.47 | $ |
| Book-Value pS | 5.04 | $ |
| Tangible Book-Value pS | 5.04 | $ |
| Cash Flow pS | 0.17 | $ |
| Free Cash Flow pS | 0.34 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 3.89 | |
| Price/Tangible Book Ratio | 3.89 | |
| Price/Cash Flow | 115.3 | |
| Price/Free Cash Flow | 57.6 | |
| P/E as % of Industry Group | 1,379.0 | % |
| P/E as % of Sector Segment | 1,098.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 0.6 | 102 | 9,299 | 51,675 |
| 4 Weeks | 19.79 | 19.26 | 19.51 | 0.5 | 107 | 8,102 | 162,040 |
| 13 Weeks | 19.79 | 18.37 | 18.72 | 4.7 | 110 | 4,576 | 288,290 |
| 26 Weeks | 19.79 | 16.51 | 19.35 | 1.3 | 102 | 6,919 | 871,774 |
| 52 Weeks | 19.98 | 11.55 | 13.81 | 41.9 | 127 | 5,485 | 1,371,206 |
| YTD | 19.98 | 16.51 | - | -1.5 | 97 | 6,984 | 1,033,633 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 19.57 | 19.58 | 19.19 | 19.08 | 18.70 | 1.20 | 1.85 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 171.08 | 81.2 | 34.80 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | -2.51 | NA | 3.46 |
| R&D | 22.37 | NA | 34.55 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 89.2 | 89.2 | 25.6 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.13 | 0.13 | 0.37 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 77.03 |
| Current Ratio | 17.4 |
| Quick Ratio (Acid Test) | 17.2 |
| Liquidity Ratio (Cash) | 15.89 |
| Receivables Turnover | 2.5 |
| Average Collection Period | 144 |
| Working Capital/Equity | 81.2 |
| Working Capital pS | 3.93 |
| Cash-Flow pS | 0.04 |
| Free Cash-Flow pS | 0.33 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 46.23 |
| Financial Leverage Ratio (Assets/Equity) | 1.1 |
| Debt Ratio | 5.1 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 0.5 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.00 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 0.68 |
| Tobin's Q Ratio | 3.86 |
| Current P/E Ratio - LTM | 280.00 |
| Enterprise Value (EV)/EBITDA | -119.56 |
| Enterprise Value (EV)/Free Cash Flow | 51.77 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 3.89 |
| Price/Book Ratio - LTM | 3.89 |
| Price/Cash Flow Ratio | 115.3 |
| Price/Free Cash Flow Ratio - LTM | 57.6 |
| Price/Sales Ratio | 13.80 |
| P/E Ratio (1 month ago) - LTM | 279.0 |
| P/E Ratio (26 weeks ago) - LTM | 276.4 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 1,379.0 |
| P/E as % of Sector Segment | 1,098.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 280.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 0.24 |
| Tangible Book Value pS - LTM | 5.04 |
| Book Value pS - LTM | 5.04 |
| Capital Invested pS | 4.82 |
| Cash pS - LTM | 1.47 |
| Cash Flow pS - LTM | 0.17 |
| Free Cash Flow pS - LTM | 0.34 |
| Earnings pS (EPS) | -0.06 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 26.80 |
| Free Cash Flow Margin 5YEAR AVG | -1,235.23 |
| Net Profit Margin | -4.6 |
| Net Profit Margin - 5YEAR AVRG. | -44.8 |
| Equity Productivity | 0.25 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.25 |
| Return on Capital Invested (ROCI) | -1.2 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -5.5 |
| Assets Productivity | 0.20 |
| Return on Assets (ROA) | -1.1 |
| Return on Assets (ROA) - 5YEAR AVRG. | -5.2 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | -1.1 |
| EBIT Margin - LTM | 5.1 |
| Pre-Tax Profit Margin | -4.6 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | -45.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.9 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 94 |
| Revenue per Employee | 284,959 |
| Net Income per Employee | -13,036 |
| Average Collection Period | 94 |
| Receivables Turnover | 2.5 |
| Day's Inventory Turnover Ratio | 0 |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 2.46 |
| Assets/Revenue | 5.00 |
| Net Working Capital Turnover | 0.31 |
| Fixed Assets Turnover | 1.32 |
| Total Assets Turnover | 0.2 |
| Revenue per $ Cash | 1.04 |
| Revenue per $ Plant | 1.92 |
| Revenue per $ Common Equity | 0.25 |
| Revenue per $ Capital Invested | 0.25 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 24.0 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 32.5 |
| Research & Devlopment (R&D) as % of Revenue | 95.1 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 95.1 |
|
|  
| | |  |  | |
| |